Antibiotic resistance among Helicobacter pylori strains is the major cause of eradication
failure. Resistance prevalence is dynamic and can greatly vary among countries over the …

Increasing rates of Helicobacter pylori resistance are associated with multiple clinical
challenges. Bacterial factors linked to H. pylori resistance are mutations, efflux pumps, and …

Helicobacter pylori infection causes chronic gastritis, which can progress to severe
gastroduodenal pathologies, including peptic ulcer, gastric cancer and gastric mucosa …

Background Treating Helicobacter pylori infection according to antibiotic resistance has
been frequently recommended. However, information on its real effectiveness is scarce. Aim …

Helicobacter pylori is one of the most common cause of human infections. Infected patients
develop chronic active gastritis in all cases, which can lead to peptic ulcer, atrophic gastritis …

Despite the declining trend of Helicobacter pylori (H. pylori) prevalence around the globe,
ongoing efforts are still needed to optimize current and future regimens in view of the …

Background One‐week triple therapy with vonoprazan is endorsed by Japanese guidelines
as an alternative to proton pump inhibitor (PPI)‐based triple therapy for first‐line …

Helicobacter pylori (Hp) is a prevalent organism infecting almost half the global population. It
is a significant concern, given its associated risk of gastric cancer, which is the third leading …

Ethnopharmacological relevance The large number of secondary derivatives have been
isolated from the genus Salvia with about 700 species, and used in the pharmacopoeia …

(1) Background: Whether standard bismuth quadruple therapy (BQT) is superior to
concomitant therapy for the first-line treatment of Helicobacter (H.) pylori infection is unclear …